HUTCHMED (China) (HKG:0013) reported an attributable net income of $37.7 million in 2024, down from $100.8 million a year earlier.
Earnings per share were $0.04, a decline from $0.12 in the same period last year, according to a Wednesday filing with the Hong Kong bourse.
Revenue dropped to $630.2 million from $838.0 million the previous year.
Looking ahead, the biotech firm expects to generate a consolidated revenue of $350 million to $450 million for its oncology and immunology business.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。